Catholic University Industry Academic Cooperation Foundation

Postech Academy-industry Foundation

Korea Research Institute of Chemical Technology

Avixgen Inc.

Bmi Korea Co., Ltd

Biopolymed Inc.

Jun-Sub Choi

Choun-Ki Joo

Min Jung Kim

Sung-Hee Lee

Sung-Eun Yoo

Sei Kwang Hahn

Yoon Keun Kim

Jin-Ha Park

Yi Yong Baek

Kyu-Yang Yi

Geun-Hyeog Lee

Hye Cheong Koo

Jee-Hee Suh

Myung-Ok Park

Eun Ju Oh

Koo Woo

Hyemin Kim

Young Myeong Kim

Yeong-Jun Baik

Jeong-A Yang

Ki Su Kim

Kitae Park

You Me Tae

Yun-Seok Cho

Hye-Sung Lee

Seung Kew Yoon

Dong Keon Lee

Nack-Jeong Kim

Jae-Sik Yang

Wonhee Hur

Young-Ill Lee

Kyung-A Kim

Sung-Sik Bang

Yeryang Khim

Steven Hyun Seung Lee

The present invention provides a pharmaceutical composition for preventing or treating macular degeneration, which comprises benzopyran derivatives substituted with secondary amines including imidazole or pharmaceutically acceptable salts thereof as an active ingredient. The pharmaceutical composition of the present invention may be used in the form of eye drops.

Pharmaceutical composition for preventing or treating macular degeneration

The present invention relates to a composition for treating an ocular inflammatory disease, comprising hydrophilic sulfasalazine and hyaluronic acid, and a preparation method therefor. Furthermore, the present invention relates to a method for treating an ocular inflammatory disease, which comprises administering, to an individual, a therapeutically effective amount of hydrophilic sulfasalazine and hyaluronic acid.

Eye drop composition for treating ocular inflammatory disease and preparation method therefor

Provided are a tetrapeptide for inhibiting VEGF-induced angiogenesis and a use thereof, and particularly, provided is a peptide having the amino acid sequence of R-X1-X2-E (wherein X1 is leucine (L), isoleucine (I) or valine (V), and X2 is tyrosine (Y) or phenylalanine (F)) for inhibiting angiogenesis, or preventing, improving or treating cancer. This research was supported by grants from the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (MSIP), Republic of Korea, in 2011 and 2013 [NRF-2011-0028790 and 2013M3A9B6046563]. The tetrapeptide may effectively inhibit VEGF-induced angiogenesis or growth of cancer cells without a risk of side effects, and therefore may be expected to exhibit an excellent anticancer effect.

Tetrapeptide having effect of inhibiting VEGF-induced angiogenesis and use thereof

The present invention relates to a composition for inhibiting after-cataract including a hydrophilic sulfasalazine; a high content of hyaluronic acid; and a carrier containing an aqueous solution, and a method of preparing a composition for inhibiting after-cataract including the steps of adding hyaluronic acid powder to a hydrophilized sulfasalazine; and mixing the same with a specific condition.

Composition for inhibiting after-cataract and method of preparing the same

The present invention relates to a drug delivery composition comprising a hyaluronic acid-peptide conjugate micelle and a production method thereof. According to the drug delivery composition and the production method of the drug-loaded, hyaluronic acid-peptide conjugate micelle of the present invention, the reaction for encapsulating can proceed in a mixed solvent of an aqueous solvent and an organic solvent. Therefore, the present invention can be applied to various types of water-insoluble active components and the biocompatible and biodegradable derivative can encapsulate a drug to provide a drug-loaded micelle, which is safe to be applied for human bodies. Moreover, the micelle has a therapeutic effect from the peptide contained therein, which can act in combination with the drug as packing therein. Therefore, the drug delivery composition and its production method can be utilized in the field of producing a sustained release formulation with an extended duration of the medicinal effect.

Drug delivery system using hyaluronic acid-peptide conjugate micelle

The present invention relates to a siRNA which targets mRNA of the NF-Kappa B p105 gene to cause its degradation by RNAi induction. In addition, the present invention provides a pharmaceutical composition for the treatment of diseases associated with aberrant cell proliferation and migration, comprising the siRNA and delivery vehicle capable of intracellular delivery of the same.

siRNA of NF-kB p105 for inhibiting cell proliferation and migration and a composition comprising same

Growing community of inventors

Yongin-si, South Korea

Jun-Sub Choi